Next generation drug conjugates for cancer treatment

Project Information

Syndivia

Grant agreement ID: 735764

DOI

10.3030/735764

Project closed

EC signature date 24 July 2016

Start date 1 July 2016

End date 30 November 2016

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

SYNDIVIA
France

Periodic Reporting for period 1 - Syndivia (Next generation drug conjugates for cancer treatment)

Reporting period: 2016-07-01 to 2016-11-30

Summary of the context and overall objectives of the project

Pancreatic cancer has the lowest survival rate of all cancers and is the fourth leading cause of death by cancer in Europe. Syndivia has developed SDV1001, a small molecule prodrug customised to target the pancreatic tumour microenvironment upon conjugation with serum albumin found in blood. The formulation offers a specialist target therapy for treating cancer without harming healthy cells surrounding the tumour. The objectives of the innovation project are to advance the drug through preclinical toxicology studies and commence Phase I/IIa clinical trials with cancer patients.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

Syndivia undertook a full analysis of the both the technical and business potential of the SDV1001 prodrug. Syndivia analysed results of early preclinical trials and the efficacy of the product was proven through the treatment of mice. The response to SDV1001 displayed 92-100% tumour regression and no noticeable side effects. Syndivia also evaluated the strategy for out-licensing later development and performed detailed projections for the company growth. Syndivia also outreached many potential customers and stakeholders building a strong base in the oncology and pharma networks.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The expected outcome of the project is to gain first results from clinical trials and advance toward the out-licensing of the prodrug. If clinical trials are successful, the SDV1001 will be a highly valuable investment for pharmaceutical companies. The SDV1001 development will boost economic growth and create jobs within Syndivia and on a wider scale with CMOs and CROs in Europe.

biomolecule-conjugation.png